Bausch Health Companies Inc. (NYSE:BHC) Shares Sold by Deutsche Bank AG

Deutsche Bank AG cut its position in shares of Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 17.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 2,129,711 shares of the company's stock after selling 440,630 shares during the quarter. Deutsche Bank AG owned 0.59% of Bausch Health Companies worth $17,165,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of BHC. Maple Rock Capital Partners Inc. boosted its stake in Bausch Health Companies by 156.7% during the fourth quarter. Maple Rock Capital Partners Inc. now owns 5,300,000 shares of the company's stock valued at $42,718,000 after buying an additional 3,235,100 shares in the last quarter. Compass Rose Asset Management LP lifted its holdings in Bausch Health Companies by 366.7% in the 4th quarter. Compass Rose Asset Management LP now owns 2,100,000 shares of the company's stock valued at $16,926,000 after acquiring an additional 1,650,000 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in Bausch Health Companies by 46.3% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,770,793 shares of the company's stock valued at $38,501,000 after acquiring an additional 1,510,445 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Bausch Health Companies by 62.0% during the 4th quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company's stock valued at $26,614,000 after purchasing an additional 1,263,706 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC grew its stake in shares of Bausch Health Companies by 989.1% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 611,890 shares of the company's stock worth $4,940,000 after purchasing an additional 555,709 shares during the last quarter. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BHC has been the subject of a number of research reports. Jefferies Financial Group restated a "hold" rating and set a $8.00 target price (down from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. Royal Bank of Canada upped their target price on Bausch Health Companies from $8.50 to $10.00 and gave the company a "sector perform" rating in a report on Friday, May 2nd. Finally, StockNews.com lowered Bausch Health Companies from a "buy" rating to a "hold" rating in a research report on Saturday, May 10th. One investment analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company. Based on data from MarketBeat.com, Bausch Health Companies presently has an average rating of "Hold" and a consensus price target of $7.42.

Bausch Health Companies Stock Down 2.1%

Shares of NYSE:BHC opened at $4.57 on Thursday. The company's fifty day moving average is $5.64 and its two-hundred day moving average is $7.03. The company has a market cap of $1.66 billion, a P/E ratio of -38.08, a price-to-earnings-growth ratio of 0.37 and a beta of 0.34. Bausch Health Companies Inc. has a 12-month low of $3.96 and a 12-month high of $9.85.

Bausch Health Companies (NYSE:BHC - Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). The business had revenue of $2.56 billion for the quarter, compared to analysts' expectations of $2.51 billion. Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. Equities research analysts anticipate that Bausch Health Companies Inc. will post 4.41 earnings per share for the current year.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc. (NYSE:BHC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.